The Impact of rs767455 and rs1061622 Polymorphisms on Treatment Outcomes in Iraqi Ankylosing Spondylitis Patients Taking Etanercept | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 227, Volume 90, Issue 2, January 2023, Page 3488-3494 PDF (850.54 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2023.291469 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Shaimaa S. Khudhur  ; Eman S. Saleh; Mohammed H. Alosami
| ||||
| Abstract | ||||
| Background: Ankylosing spondylitis (AS) is inflammation of the sacroiliac joints and spine, associated with clinical symptoms such as pain and stiffness in the vertebral column, after which, in a considerable number of individuals, new bone growth occurs. Objective: The current research study attempted to find out whether the presence of SNPs in TNF receptor [TNFRSF1A (rs767455), TNFRSF1B (rs1061622)] encoding genes could influence patients' outcomes to etanercept in a specimen of Iraqi AS patients. Patients and methods: Sixty patients with established AS receiving only etanercept were selected to be enrolled in this research with a mean age of 40.75 ± 8.67 years, 51 patients of them were males and only 9 patients were females. Patients were classed as "responders" if just obtained a BASDAI 50 clinical response and as "non-responders" if they can't achieve a BASDAI 50 clinical elaboration after at least 6 months treatment. After PCR products amplification of purified blood DNA, TNF receptor (TNFRSF1A and TNFRSF1B) genes SNPs were established by Sanger sequencing. Results: The analysis of this study expressed that there was a significant incidence of TT genotype of rs1061622 (P = 0.022) in responder group, whereas the TG genotype of the same single nucleotide polymorphism (SNP) was considerably present in the group that did not respond (P = 0.002). Finally, a non-significant difference existed in alleles and genotypes frequency between responder and non-responder groups of rs767455 SNP in TNFRSF1A gene. Conclusions: The wild TT genotype of rs1061622 predicts etanercept responsiveness in ankylosing spondylitis patients. The TG genotype of the same SNP increases the probability of non-responding. | ||||
| Keywords | ||||
| Ankylosing spondylitis; Genetic polymorphism; TNFRSF1A; TNFRSF1B; Etanercept | ||||
|
Statistics Article View: 97 PDF Download: 278 |
||||
